Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023

Rhea-AI Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD) will host a business update conference call and webcast on November 14, 2023, at 8:30 AM EST. The call will provide a business update, including an overview of the Company's operations and third-quarter 2023 financial results. The webcast can be accessed on luciddx.com, and the conference call can be accessed by telephone. A replay will be available on the website for 30 days.

Conference Call and Webcast at 8:30AM Eastern Time

NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, November 14, 2023, at 8:30 AM EST. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third-quarter 2023 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-833-816-1418 and international listeners should dial 1-412-317-0511. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test is performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device. EsoGuard and EsoCheck are the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-14-2023-301972766.html

SOURCE Lucid Diagnostics

FAQ

When is Lucid Diagnostics hosting a business update conference call and webcast?

Lucid Diagnostics is hosting a business update conference call and webcast on November 14, 2023.

What will be discussed during the conference call?

The conference call will provide a business update, including an overview of the Company's operations and third-quarter 2023 financial results.

How can the webcast be accessed?

The webcast can be accessed on the investor relations section of Lucid Diagnostics' website at luciddx.com.

How can the conference call be accessed by telephone?

U.S.-based callers should dial 1-833-816-1418 and international listeners should dial 1-412-317-0511. All listeners should provide the operator with the conference call name 'Lucid Diagnostics Business Update' to join.

How long will the replay be available?

A replay of the conference call will be available for 30 days on the investor relations section of Lucid Diagnostics' website at luciddx.com.